SCHEMBL6087485

SCHEMBL6087485

CC1OC(=C2C(=O)Nc3ccccc32)c2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 4/20 0.42
ACVR1 Q04771 2/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
PDGFRA P16234 1/20 0.42
FER P16591 1/20 0.42
LTK P29376 1/20 0.42
CDK8 P49336 1/20 0.42
DYRK1B Q9Y463 1/20 0.42
POLB P06746 2/20 0.41
PBRM1 Q86U86 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
CSNK1G1 Q9HCP0 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PARP1 P09874 1/20 0.40
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
DYRK1A Q13627 1/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087481 1.00 LRRK2 (0.42) LRRK2ACVR1MAOAMAOBPDGFRA
SCHEMBL20711175 0.86 TGM2 (0.40) LRRK2MEN1KMT2ATGM2
SCHEMBL14725096 0.86 TGM2 (0.40) LRRK2MEN1KMT2ATGM2
SCHEMBL14715504 0.82 SMN1; SMN2 (0.42) LRRK2ACVR1MAOAMAOBPDGFRA
SCHEMBL14715503 0.82 SMN1; SMN2 (0.42) LRRK2ACVR1MAOAMAOBPDGFRA
SCHEMBL6104067 0.80 AKR1B1 (0.40) MAOAMAOBMEN1KMT2AALDH1A1
SCHEMBL6104068 0.80 AKR1B1 (0.40) MAOAMAOBMEN1KMT2AALDH1A1
SCHEMBL6086475 0.79 LRRK2 (0.39) LRRK2ACVR1MAOAMAOBPDGFRA
SCHEMBL14725083 0.79 LRRK2 (0.39) LRRK2ACVR1MAOAMAOBPDGFRA
SCHEMBL6086479 0.79 LRRK2 (0.39) LRRK2ACVR1MAOAMAOBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP disclosed
US-7060844-B2 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-06-13 US disclosed
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-01-05 US disclosed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 LRRK2 545/4885ACVR1 1142/4885MAOA 1164/4885
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 LRRK2 497/4885ACVR1 1197/4885MAOA 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.